Lilly van de Venn - HT-DISCOVER

In the rapidly growing field of genome editing, a significant challenge faced by genome editing companies, pharmaceutical firms, and research institutions is the accurate detection of off-target effects. Off-targets—unintended modifications in the genome—pose serious risks, including potential pathogenic outcomes, which can compromise the safety and efficacy of gene therapies. Current methods for off-target detection either lack precision, are too time-consuming, or require prohibitively large amounts of cellular material, making them unsuitable for clinical and high-throughput applications.
HT-DISCOVER addresses this critical problem by providing a highly accurate, efficient, and scalable solution for off-target detection in genome editing. Our technology significantly reduces the cell input requirements and processing time while maintaining the highest levels of precision which enhances public trust and regulatory approval for gene-editing interventions.